问题 › 竞争对手正在抢走我们的客户 › 健康科技与数字健康
输给竞争对手更多时候是结果定位问题，而非市场份额风险问题，二者需要截然相反的应对方式。 对数字健康公司而言更难的原因在于结构：结果风险签约速度快于公司判断自身能否承担的速度——12个月测量窗口对上11个月销售周期。因此任何可信答案都必须同时把握风险收入份额与参与率，而这正是大多数内部分析停滞之处，因为二者分属不同系统。
输给竞争对手更多时候是结果定位问题，而非市场份额风险问题，二者需要截然相反的应对方式。 对数字健康公司而言更难的原因在于结构：结果风险签约速度快于公司判断自身能否承担的速度——12个月测量窗口对上11个月销售周期。因此任何可信答案都必须同时把握风险收入份额与参与率，而这正是大多数内部分析停滞之处，因为二者分属不同系统。
当竞争对手开始胜出时，业务内部给出的第一解释总是风险份额或PMPM。这偶尔正确。更常见的情况是对手在归因结果上选择了更窄的承诺，并在其中击败你，而销售团队会将其视为价格问题，因为PMPM是成交前最后讨论的内容。
区分二者很重要，因为应对方式互不相容。如果真是风险份额问题，你要么匹配并重新定价整个账簿，要么接受该细分市场的流失。如果是定位问题，匹配风险份额只会资助对手优势，同时破坏你的毛利率。
判断方式并不光鲜：把最近二十次失单的原因按归因结果分段。风险份额问题会均匀出现。定位问题则会集中出现。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 失单集中于一个细分或一个用例，而非在注册成员中均匀分布
✓ 销售团队要求降低PMPM或提高风险份额，而不是要求不同的参与率或归因结果证明
✓ 竞争对手比你更小、更专注
通常会让情况更糟的做法。 既匹配风险份额又保留原有定位，结果同时失去毛利率和论据。
It is for you if you run or finance a digital health company and losses concentrate in one segment or one use case rather than spreading evenly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Reduce downside exposure from $7.1M outcomes shortfall to $4.2M while maintaining upside participation in 34 health-plan contracts.
The leak it closes. $2.9M gross profit protected annually through downside cap (difference between $7.1M shortfall at 38% vs $4.2M shortfall at 25%)
The assumption it rests on. Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate — the engine put the probability at 0.7.
| Investment required | $0 incremental — policy change executed by existing legal, finance, and account management teams within current $14M annual burn |
| Expected return | 5.2× on zero incremental investment — derived from $4.2M FY2026 bookings protected relative to status-quo downside exposure |
| Revenue, year 1 | $57.8M ARR (25% at-risk share = $15.5M at-risk revenue vs $23.6M status quo) |
| Revenue, year 2 | $61.4M ARR (assuming 80% contract renewal at 25% cap) |
| Revenue, year 3 | $68.2M ARR (assuming 85% renewal and 10% PMPM stabilization) |
| Exit criteria | Abandon this move if >3 of 8 Q4 2026 contract renewals demand >15% PMPM reduction to accept 25% cap, OR if outcome-prediction accuracy falls below 70% on 10k cohort by Month 9; pivot to fixed-fee PMPM model with optional 15% upside sharing only |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 竞争基准与定位, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
仅当你能以对方价格服务该细分且仍有利润，且愿意为已支付更高价格的客户重新定价时。选择性匹配通常是市场注意到后无法兑现的承诺。
靠专注而非广度。资金更雄厚的对手可以到处花钱，却无法在单一领域超越你的专注，因此收窄承诺通常胜过扩展功能集。
那诚实的答案就是带时间表和成本的产品决策，而非营销回应。损害性结果是为一处营销无法弥补的差距花费一年时间做文案。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית